Goldman Sachs Group Inc (GS)vsWest Pharmaceutical Services Inc (WST)
GS
Goldman Sachs Group Inc
$841.84
-2.30%
FINANCIAL SERVICES · Cap: $250.66B
WST
West Pharmaceutical Services Inc
$247.02
+0.71%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Goldman Sachs Group Inc generates 1832% more annual revenue ($59.40B vs $3.07B). GS leads profitability with a 28.9% profit margin vs 16.1%. GS appears more attractively valued with a PEG of 1.43. GS earns a higher WallStSmart Score of 73/100 (B).
GS
Strong Buy73
out of 100
Grade: B
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+52.4%
Fair Value
$1768.48
Current Price
$841.84
$926.64 discount
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$247.02
$178.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.3%
Keeps 29 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
15.2% revenue growth
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : GS
The strongest argument for GS centers on Market Cap, Operating Margin, Profit Margin. Profitability is solid with margins at 28.9% and operating margin at 38.3%. Revenue growth of 15.2% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : GS
The primary concerns for GS are Free Cash Flow.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
GS profiles as a growth stock while WST is a mature play — different risk/reward profiles.
GS carries more volatility with a beta of 1.34 — expect wider price swings.
GS is growing revenue faster at 15.2% — sustainability is the question.
WST generates stronger free cash flow (175M), providing more financial flexibility.
Bottom Line
GS scores higher overall (73/100 vs 55/100), backed by strong 28.9% margins and 15.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Goldman Sachs Group Inc
FINANCIAL SERVICES · CAPITAL MARKETS · USA
The Goldman Sachs Group, Inc., is an American multinational investment bank and financial services company headquartered in New York City. It offers services in investment management, securities, asset management, prime brokerage, and securities underwriting. It also provides investment banking to institutional investors.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other CAPITAL MARKETS Stocks
Want to dig deeper into these stocks?